

Thank you for joining

The presentation will begin shortly





Rise to Immunize® Monthly Webinar

Expanding and Extending the RIZE Campaign

Stephen Shields, MPH, AMGA Research and Analytics





Campaign Updates

- Campaign Spotlight: Hepatitis B Foundation
- AC24 highlights
- Expansion/ Extension Overview

Expanding and Extending the RIZE Campaign


 Stephen Shields, MPH, AMGA Research and Analytics

Q&A Session



Webinar Reminders





Today's webinar recording will be available the **week** of 04/22

- Will be sent via email
- Will be available on website



Ask questions during the webinar using the **Q&A feature**

•Questions will be answered at the end of the presentation

(RiseToImmunize.org → "Resources" → "Webinars")

Campaign Spotlight





AC24 Highlights









"While we are proud of the innovation reflected in our new vaccine, we are not complacent. **We** continue to be committed to a relentless pursuit of scientific innovation."

- Andrew Martin, MBA, US Vaccines Lead, Pfizer, Inc. at the AMGA Foundation Celebration

More Vaccines!



Influenza

Pneumococcal

Td/Tdap

Zoster



RSV


COVID-19

Hepatitis B

More Time!



The RIZE campaign will be extended through 2027





Through the RIZE campaign, you can:

Continue to tackle immunization barriers and inequities.

Focus on additional vaccines of your choosing.

Hardwire changes for sustainability.



Together we can administer 30 million vaccines by 2027 through comprehensive & equitable vaccine initiatives.

How to add new measures:



Use the QR code to access the Measure Upgrade Form



✓ Or email <u>RiseToImmunize@amga.org</u> and we can assist you!



Thank you to all of our sponsors who have committed to the expansion and extension!

Today's Speaker





Stephen Shields, MPH, Lead Population Health Research Analyst, *AMGA Research and Analytics*







Extending and Expanding RIZE!




Agenda



- Overview
- **Expansion Measure Details**
- Timeline
- What's next? ©

Why Measures?







Extension and Expansion

Extension and Expansion



- Extension = the campaign will run through 2027
 - Data reports through Q2 2027, but campaign will run though Q4 2027
- Expansion = addition of 3 new measures
 - Age-based CDC recommendations

Measures	Age Group		
RSV*	60+		
COVID-19	19+		
Hepatitis B	19-59		

^{*}respiratory syncytial virus

Extension and Expansion



- Basic and Core tracks will remain the same
 - Bundle measure will remain unchanged
- Each extension measure will be an optional add-on
 - One year of baseline data, Measurement Year '23 (Q3 2023 Q2 2024)
- Update Measure Specifications (v2.0) are available on the <u>Rise to Immunize® website</u>
- A separate Expansion Measures Value Set will be sent via email in summer 2024

Campaign Measures



Measures	Age Group	Basic Track	Core Track
Influenza	19+	\checkmark	√
Pneumococcal	66+	\checkmark	\checkmark
Td/Tdap	19+		\checkmark
Zoster	50+		\checkmark
Bundle	66+		\checkmark
RSV	60+	Optional	Optional
COVID-19	19+	Optional	Optional
Hepatitis B	19-59	Optional	Optional




Reminder: Active Patient Population

Active Patient Lookback Period (APL)



- Spans from 15 months prior to Q3 of each MY to the end of the Current Measurement Period (MP)
 - Resets at the beginning of each MY (Q3)
- Patients with specified activity in the Active Patient Lookback Period (APL) will be included



Active Patient Population



Inclusion

1. Age 19–99 on the first day of the Measurement Year (MY) (July 1st),

AND

2. Completed ≥1 ambulatory visit in the APL with any specialty

AND

- 3. have EITHER
 - an Assigned PCP, OR
 - ≥1 ambulatory visit with a PCP in the APL.

Exclusion

- 1. Evidence of hospice or palliative care in the APL, OR
- 2. Death prior to the end of the RQ.

Per NAC recommendations, not all exclusions in the HEDIS® AIS measure (e.g., history of immunocompromising conditions) are used in Rise to ImmunizeTM.

For Organizations that elect to use the Assigned PCP designation, patients meeting EITHER criterion (Assigned PCP OR ≥1 visit with a PCP) should be considered eligible for the APL.

If Assigned PCP is not a reliable designation at your organization, individual HCOs can elect to only use ≥1 visit with a PCP in the APL.



Expansion Measure Details

RSV



Proportion of patients who ever received the RSV vaccination* Denominator

All patients aged 60+

Numerator Part A

Patients who received RSV vaccine during the Measurement Year


Numerator Part B

 Patients who received RSV vaccine prior to the Measurement Year or had an adverse reaction caused by the RSV vaccine

^{*}subject to change per upcoming ACIP recommendation (e.g., every 2 years)

RSV





COVID-19



Proportion of patients who received the COVID-19 vaccination in the Measurement Year*

Denominator

All patients aged 19+


Numerator

 Patients who received one COVID-19 vaccination during the Measurement Year or had an adverse reaction to a COVID-19 vaccine

^{*}subject to change per upcoming ACIP recommendation

COVID-19





Hepatitis B



Proportion of patients who completed the Hepatitis B series during or prior to the Measurement Year

Denominator

All patients aged 19-59

Numerator Part A


Patients that completed the series during the Measurement Year

Numerator Part B

Patients that completed the series prior to the Measurement Year

Hepatitis B





Documentation and Administration



HCOs should ultimately use their OWN definitions and policies of vaccination documentation

Influenza, COVID-19

Recommend accepting credible patient self-reports

Pneumo., Tdap, Zoster, RSV, Hep B

Recommend requiring documentation stating that the vaccination was administered

Value Sets and Data Sources



- An Expansion Value Set will be sent via email
- Data elements can be derived from
 - medical and pharmacy claims and records
 - (electronic) practice management systems (PM or EPM)
 - electronic health record systems (EHR)
 - health maintenance tables
 - disease registries
 - population health software
 - local/state/regional vaccine registries
 - other health records, etc.
- Recorded or collected directly at point-of-care, or from another data source



Expansion and Extension Reporting Timelines



Reporting Timelines for Expansion Measures

The first Expansion Measure Reporting Quarter is Q3 2024, therefore...

... the first report with the additional expansion measures is due on October 15th, 2024

This report should include the previous Measurement Year (MY 2023) as Baseline



Reporting Timelines for Expansion Measures



Reporting Process



- Reporting process will remain the same
- Send your Reporting Template to <u>DataforRize@amga.org</u> each quarter



What's next?

What's next?



An updated reporting template with added extension years and expansion measures (also this summer)

And...

Introducing the RIZE dashboard



A new way to view RIZE data!



RIZE Dashboard



- All features from the previous pdf reports will be available in the dashboard
- Dashboard will streamline reporting, allow highlighting of your group
 - Exploring stratifications- see how you compare to organizations of similar size!
- Dashboard will be accessible from the RIZE website, like how previous reports were accessed
- Backend data remains on AMGA-owned servers

Campaign Communication



Add the campaign email to your safe sender list RiseTolmmunize@amga.org

If you need assistance setting up measures or have any questions, please email us! We'd be happy to set up a meeting.

Questions





Upcoming Webinar





Topic: Making Respiratory Health a Priority: Insights for Health Care Professionals



Date/ Time: Thursday, May 16 at 2pm ET



Presenter: Carrie Regnier, BS, BSN, MPH, RN, *AMGA National*

Questions?





Submit your questions using the **Q&A feature** at the bottom of the screen

